Last reviewed · How we verify
NCT03261856
Clinical Utility of Breath Tests in GI
trial in Small Intestinal Bacterial Overgrowth in 1,080 participants. Completed in 31 December 2017.
31 December 2017
Quick facts
| Lead sponsor | Augusta University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,080 |
| Start date | 31 August 2011 |
| Primary completion | 31 December 2017 |
| Estimated completion | 31 December 2017 |
| Sites | 1 location across United States |
Conditions studied
- Small Intestinal Bacterial Overgrowth — all drugs for Small Intestinal Bacterial Overgrowth →
- Lactose Intolerance — all drugs for Lactose Intolerance →
- Fructose Intolerance — all drugs for Fructose Intolerance →
- Glucose Intolerance — all drugs for Glucose Intolerance →
Sponsor
Augusta University
Who can join
18 and older, any sex, with Small Intestinal Bacterial Overgrowth or Lactose Intolerance. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Bloating, gas, pain and diarrhea are common complaints. Routine investigations are negative; these patients are labeled as IBS. In these patients, whether testing for carbohydrate malabsorption or small intestinal bacterial overgrowth (SIBO) is useful is unclear. Investigators aim to assess the prevalence of SIBO, fructose and lactose intolerance, the usefulness of breath tests, and predictive value of pre-test symptoms.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03261856
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Small Intestinal Bacterial Overgrowth
Currently open trials in the same condition.
- NCT05967871 — Pilot Feasibility Study of Fecal Microbiota Transplant for the Treatment of Small Intestinal Bacterial Overgrowth · Phase 1 · recruiting
- NCT06298409 — Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan® · Phase 1 · recruiting
Other Augusta University trials
Trials by the same sponsor.
- NCT07341841 — Assessing Obesity Related Risk Factors in Adult Population: A Genetic and Behavioral Study · NA · enrolling by invitation
- NCT07489144 — CO-creating Novel, Feasible, and Inclusive Research Methods · NA · active not recruiting
- NCT06514014 — Transition From Donor Milk: a Feasibility Study · NA · recruiting
- NCT06907992 — A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated C · not yet recruiting
- NCT06058169 — Effects of Home Base Whole-body Vibration in Osteoarthritis. (VIBE-Rx2) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03261856 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Augusta University
- Last refreshed: 17 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03261856.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing